ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Based on its recent analysis of the clinical diagnostics market, Frost & Sullivan recognized GenPath Diagnostics, a business unit of BioReference Laboratories, Inc ...
Cambridge-based GenPath Pharmaceuticals Inc., a drug discovery and development company focused on the treatment of cancer and other diseases, announced today that it has entered into a multi-year ...
ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts ...
ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Bio-Reference Laboratories, Inc. (“BRLI”) (NASDAQ: BRLI) announced today that it has completed an equity investment in InCellDx, Inc. (“InCellDx”), a privately ...
OPKO Health, Inc.’s OPK BioReference Laboratories, Inc. along with its specialty oncology division, GenPath, recently launched OnkoSight Advanced. It is a next-generation sequencing (NGS) assay that ...
Less than a month after raising $42.7 million in a Series B round, GenPath Pharmaceuticals Inc. said it has nailed down a multiyear cancer deal with Merck & Co. Inc. worth up to $100 million, ...
Bio-Reference Laboratories, Inc. has announced that K-ras mutation testing for patients with metastatic colorectal (mCRC) or non-small-cell lung (NSCLC) cancers will now be available through the ...
GenPath Pharmaceuticals Inc., Cambridge, Mass., raised $42.7 million in series B funding. Flagship Ventures led the round, which included Highland Capital Partners, Oxford Biosciences, existing ...
GenPath Pharmaceuticals Inc. said today that it has raised $15.5 million in a series A financing round. MPM Capital led the round and was joined by Venrock Associates, Prospect Venture Partners, ...
CAMBRIDGE, Mass. -- Closely held GenPath Pharmaceuticals Inc. said it signed a multiyear agreement with Merck & Co. covering its cancer-research techniques that has a potential value of $100 million ...
ELMWOOD PARK, N.J.--(BUSINESS WIRE)-- BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results